Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACR | P10323 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151496 | 0.82 | CA1 (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL18523300 | 0.82 | LMNA (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL30511388 | 0.82 | CA12 (0.36) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL21185862 | 0.81 | ACR (0.33) | CA12CA1CA2CA9ACR | |
| SCHEMBL20215490 | 0.80 | KMT2A (0.32) | KMT2AATM | |
| SCHEMBL20792054 | 0.80 | KMT2A (0.32) | KMT2AATM | |
| SCHEMBL12521220 | 0.80 | TDP1 (0.36) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL8598030 | 0.78 | TSHR (0.35) | TSHRKMT2AATMALDH1A1 | |
| SCHEMBL487067 | 0.78 | LMNA (0.46) | CA12CA1CA2CA9LMNA | |
| SCHEMBL30511373 | 0.78 | LMNA (0.52) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717852-B2 | Alkali-soluble resin additives and coating compositions including such additives | SWIMC LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1444300-A1 | METHOD FOR SOLIDIFICATION OF A LIQUID PAINT COMPONENT | DSM IP Assets B.V. (NL) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003025073-A1 | METHOD FOR SOLIDIFICATION OF A LIQUID PAINT COMPONENT | DSM IP ASSETS B.V. (NL) | 2003-03-27 | — | — | WO | disclosed |
| EP-1295915-A1 | Method for solidification of a liquid paint component | DSM N.V. (NL) | 2003-03-26 | — | — | EP | disclosed |
| US-4221687-A | BASIC INORGANIC SALT, 1,3-DIKETONE, VINYL CHLORIDE POLYMER | ARGUS CHEMICAL CORP. (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | TSHR 3921/4885CA12 4769/4885CA1 4587/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | TSHR 3945/4885CA12 4782/4885CA1 4548/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | TSHR 3921/4885CA12 4769/4885CA1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.